KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Operating Expenses (2020 - 2025)

Ginkgo Bioworks Holdings' Operating Expenses history spans 6 years, with the latest figure at $104.1 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 29.37% year-over-year to $104.1 million; the TTM value through Dec 2025 reached $485.4 million, down 38.3%, while the annual FY2025 figure was $485.4 million, 38.3% down from the prior year.
  • Operating Expenses reached $104.1 million in Q4 2025 per DNA's latest filing, down from $128.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $1.8 billion in Q4 2021 to a low of $101.2 million in Q1 2021.
  • Average Operating Expenses over 5 years is $360.9 million, with a median of $214.4 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: skyrocketed 1984.49% in 2021, then crashed 82.05% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $1.8 billion in 2021, then plummeted by 82.05% to $329.1 million in 2022, then plummeted by 35.33% to $212.9 million in 2023, then tumbled by 30.73% to $147.5 million in 2024, then dropped by 29.37% to $104.1 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Operating Expenses are $104.1 million (Q4 2025), $128.9 million (Q3 2025), and $115.1 million (Q2 2025).